Last update 21 Nov 2024

Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target
CCR5 x RT
Mechanism
CCR5 antagonists(C-C chemokine receptor type 5 antagonists), RT inhibitors(Reverse transcriptase inhibitors)
Therapeutic Areas
Immune System DiseasesInfectious DiseasesUrogenital Diseases
Active Indication
HIV Infections
Inactive Indication-
Originator Organization-
Active Organization
Oak Crest Institute of ScienceOak Crest Institute of ScienceUniversity of Texas Medical BranchUniversity of Texas Medical BranchAuritec Pharmaceuticals, Inc.Auritec Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H34N5O14P
InChIKeyVCMJCVGFSROFHV-WZGZYPNHSA-N
CAS Registry202138-50-9
View All Structures (3)

Related

1
Clinical Trials associated with Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
NCT02431273 / CompletedEarly Phase 1
Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women
100 Clinical Results associated with Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
Login to view more data
100 Translational Medicine associated with Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
Login to view more data
100 Patents (Medical) associated with Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
Login to view more data
100 Deals associated with Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 1---
HIV InfectionsPhase 1-
University of Texas Medical BranchUniversity of Texas Medical Branch
-
HIV InfectionsPhase 1-
Oak Crest Institute of ScienceOak Crest Institute of Science
-
HIV InfectionsPhase 1-
Auritec Pharmaceuticals, Inc.Auritec Pharmaceuticals, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02431273 (CTgov)
Early Phase 1
HIV Infections
10
(TDF (Single IVR))
oxhznvkuii(pwaowgwteb) = uozrxwuoth ifmqbxtdan (nlzgwvejlu, ugycabdbzk - aijjchuxvt)
View more
-
02 Jul 2019
TDF-FTC IVR
(TDF-FTC (Dual IVR))
oxhznvkuii(pwaowgwteb) = cxiteeivrr ifmqbxtdan (nlzgwvejlu, gaqpobwwsf - ddmfpymtkz)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free